An interventional study of Rutin 500 MG and Placebo in Ulcerative Colitis, sponsored by Benha University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Benha University · Not applicable, Interventional, and Supportive care
Ulcerative colitis (UC) is an inflammatory bowel disease characterized by oxidative stress and recurring inflammation in the colon. The condition can become chronic, spread, and lead to other complications.
A key player in the inflammation process is the NLRP3 inflammasome. This inflammasome's expression is heightened and activated by reactive oxygen species (ROS). Its activity is influenced by various factors, including the ubiquitin system, ion channels, and gut microbiota.
Rutin, a compound found in many fruits and vegetables, has been shown to have properties that help scavenge free radicals.
1,492 studies on the registry are indexed under Colitis, Ulcerative; 399 are open to participants now.
This study's enrollment of 60 is below the median of 71 across 1,042 interventional studies indexed under Colitis, Ulcerative.
Browse Colitis, Ulcerative studies →Benha University is the lead sponsor of 356 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients diagnosed with active Ulcerative Colitis were assigned as group UC-A
Drug: Rutin 500 MG · Diagnostic Test: fecal calprotectin
Patients diagnosed with remission Ulcerative Colitis were assigned as control group UC-B
Other: Placebo · Diagnostic Test: fecal calprotectin
Healthy volunteers provided samples as negative controls; and was assigned as group C
Diagnostic Test: fecal calprotectin
Rutin 500 mg capsules twice daily for 30 days
Placebo Tablets
Fecal calprotectin level was measured using an ELISA kit .
Success Rate of Treatment Regimens in improving the ulcerative colitis.
The proportion of patients who achieved a Simple Clinical Colitis Activity Index (SCCAI) score of 5 or less at the end of the study, which reflects the effectiveness of the treatment.
Time frame: 3~4 Months
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Benha University